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Arelationshipexistsbetweenthesleep-wakecycleandhormonesecretion,which,inwomen,isfurthermodulatedbythemenstrual
cycle.Thisinteractioncaninﬂuencesleepacrossthemenstrualcycleinhealthywomenandinwomenwithpremenstrualdysphoric
disorder(PMDD),whoexperiencespeciﬁcalterationsofcircadianrhythmsduringtheirsymptomaticlutealphasealongwithsleep
disturbances during this time. This review will address the variation of sleep at diﬀerent menstrual phases in healthy and PMDD
women, as well as changes in circadian rhythms,with an emphasis on their relationshipwith female sexhormones. It will conclude
with a brief discussion on nonpharmacological treatments of PMDD which use chronotherapeutic methods to realign circadian
rhythms as a means of improving sleep and mood in these women.
1.Introduction
Avarietyofhormones,includingmelatonin,cortisol,thyroid
stimulating hormone (TSH), and prolactin (PRL), vary
across the 24-hour day and are highly regulated by the
circadian and sleep-wake cycles. Evidence suggests that these
hormones, as well as other physiological rhythms like body
temperature, play a role in sleep organization and can
also be aﬀected by sleep itself (or lack thereof). These
relationships can be further modulated by the menstrual
cycle, since ﬂuctuations in gonadotropic and sex steroid
hormones occurring throughout the menstrual cycle can
inﬂuence sleep, body temperature, and other hormones.
Sleep disruptions are common in women, with reports
of insomnia occurring 1.5–2 times more frequently than in
men [1]. Indeed, sleep complaints commonly occur during
the postovulatory luteal phase (LP) in healthy women [2].
These complaints reach a higher severity in women suﬀering
from premenstrual dysphoric disorder (PMDD) [3], a DSM-
IV classiﬁed menstrual cycle-related mood disorder. Since
disturbed sleep and circadian rhythms have been correlated
with increased incidence of obesity and diabetes [4], cardio-
vascular disease [5], and especially depression [6], and since
depression already occurs with higher prevalence in women
[7], it is necessary to understand how neuroendocrine
changes across the menstrual cycle interact with circadian
physiology and contribute to the greater susceptibility of
sleep complaints in women.
The aim of this paper is to review studies which
investigated how the menstrual cycle, and its associated
variation in sex steroid hormones, aﬀects sleep and circadian
rhythms in both healthy women and women with PMDD.
Additionally, we will address the inconsistencies that often
characterize these experimental results, highlighting meth-
ods which can minimize various confounders, and oﬀer
suggested areas of further research. Articles were included
if they were written in English, conducted on human
research participants, and concerned changes in sleep and/or
circadian rhythms on at least two menstrual cycle phases
in healthy and/or PMDD women. Though there were no2 International Journal of Endocrinology
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Figure 1: The interaction between circadian (C) and homeostatic
(S) processes in an “opponent-process” results in an uninterrupted
8-hour nocturnal sleep episode and a wake period maintained
throughout the 16-hour day. The homeostatic drive for sleep
(illustrated as the “sleep load”) increases throughout the waking
period and reaches a peak just before habitual bedtime. The
circadian drive for alertness (illustrated as the “alerting signal”)
reaches a peak at this time and is lowest near the end of the sleep
episode. From [8].
date restrictions, menstrual cycle-related research articles
included were published between 1984 and the present.
2. Hormones and the Sleep-Wake and
Circadian Cycles
2.1. Circadian and Homeostatic Regulation of the Sleep-Wake
Cycle. The sleep-wake cycle is regulated by an interaction
between homeostatic (process S) and circadian (process
C) processes [10]. Throughout the course of the waking
day, the homeostatic drive for sleep pressure increases and
dissipates rapidly during the subsequent sleep episode. This
process has been linked to the restorative aspects of sleep
and is quantiﬁable with the amount of slow wave sleep
(SWS; stage 3+4 sleep based on standard polysomnographic
sleep analyses [11]) or more accurately slow wave activity
(SWA; power density within the 0.5–4.5Hz frequency range
based on spectral analysis of the EEG signal), which was
demonstrated to increase as a function of the duration of
prior awakening [12]. It was hypothesized that increasing
levels of adenosine in the basal forebrain during waking
contributes to the buildup of the homeostatic drive for sleep
[9].
At certain times of day, for example, just before habitual
bedtime when the homeostatic drive for sleep is at its peak,
and conversely at the end of the sleep episode when it
is at its lowest, a strong circadian drive for wakefulness
and sleepiness, respectively, counteracts process S. This
interaction, referred to as the “opponent process,” results in
uninterrupted 8-hour nocturnal sleep and 16-hour waking
episodes each day (Figure 1)[ 8, 13]. Circadian rhythms
(i.e., endogenously generated biological rhythms of about
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Figure 2: Pathways involved in the hypothalamic control of the
circadian rhythms of sleep, wakefulness and body temperature. In
the regulation of circadian sleep-wake patterns, outputs from the
SCN relay at the vSPZ, and project to the DMH. The DMH then
sends outputs to the VLPO (a sleep-activating center), and the
LHA (where orexin neurons target downstream wake-promoting
sites). The SCN regulates circadian body temperature rhythms
through a relay at the dSPZ, which projects to the MPO. SCN,
suprachiasmatic nucleus; vSPZ: ventral subparaventricular zone;
dSPZ: dorsal subparaventricular zone; DMH: dorsomedial nucleus;
VLPO: ventrolateral preoptic nucleus; LHA: lateral hypothalamic
area; MPO: medial preoptic nucleus; MCH: melanin-concentrating
hormone; TRH: thyrotropin-releasing hormone. Modiﬁed with
permission from [9].
24 hours) are observable in many aspects of human physiol-
ogy and behavior, including neuroendocrine secretion [14],
sleep propensity and architecture [10], and subjective and
EEG-based estimates of alertness [15]. The suprachiasmatic
nucleus (SCN) of the anterior hypothalamus is the mas-
ter circadian pacemaker [16] and coordinates endogenous
physiology with the external light-dark environment [17].
Sleep parameters including sleep onset latency (SOL), sleep
eﬃciency (SE),rapid eyemovement (REM)sleep, REM sleep
onset latency (ROL), and spindle frequency activity (SFA;
spectral power density within the 12–15Hz range) show a
strong circadian modulation [10].
Signals originating in the SCN generate the circadian
variation of sleep and wakefulness via major outputs to
the ventral subparaventricular zone (vSPZ) and dorsomedial
nucleus (DMH) (Figure 2)[ 9]. Some key arousal centers
involvedinthisregulationarethehistaminergictuberomam-
millary nucleus (TMN), the noradrenergic locus coeruleus
(LC), and the serotonergic dorsal and median raphe nucleus.
The principle hypothalamic center for sleep initiation is the
ventrolateral preoptic nucleus (VLPO). Activity in the VLPO
isdrivenbytheSCNviaitsprojectionstothevSPZandDMH
(Figure 2)[ 9]. Orexin neurons originating in the lateral
hypothalamic area also receive projections from the SCN via
the vSPZ and DMH, and promote wakefulness through their
inputs to the TMN, LC, and raphe nucleus [9]. The sleep-
wake system is presumed to be dependent on the mutuallyInternational Journal of Endocrinology 3
inhibitory interaction between these key arousal and sleep
centers [9]. According to this “ﬂip-ﬂop” model, sleep occurs
when the VLPO dominates, whereas waking occurs when it
isinhibitedbyhistaminergic,noradrenergicandserotonergic
inputs [9].
2.2. Circadian and Sleep-Wake Dependent Variation of
Hormones. A variety of hormones cycle with a 24-hour
rhythmicity, though some are more regulated by the endoge-
nously generated circadian system, whereas others are more
sensitive to the timing of sleep per se [14].
Melatonin and cortisol are two hormones which vary
withastrongcircadiancomponent,andarethereforereliable
markers of circadian phase, or the timing of the central
circadian oscillator [18]. The two have diﬀerent times of
peak amounts, with high melatonin levels throughout the
biological night, during which cortisol levels are minimal.
When cortisol peaks in the early morning, melatonin
secretion is already declining to reach almost undetectable
levels during the day [18]. Both hormones are sensitive
to environmental factors like retinal light exposure (which
suppresses melatonin secretion) and stress (which stimulates
cortisol release). Thus to most accurately assess their circa-
dian expression, it is advised to study them under constant
conditions, which will reduce the occurrence of confounding
“masking eﬀects” on their secretion [19].
Other hormones such as TSH and PRL cycle with a
24-hour rhythmicity but are also sensitive to sleep-wake
state.Undernormallyentrainedconditions,TSHlevelsbegin
rising before the nocturnal sleep episode, and progressively
decline throughout the sleep period [18]. Sleep has an
inhibitory eﬀect on TSH secretion [20]; therefore when
sleep is prevented, TSH levels remain high throughout
the nighttime hours. In comparison, PRL is stimulated by
sleep [20], with peak amounts detectable during the sleep
episode,andaminor,butsigniﬁcantendogenouslygenerated
circadian variation when sleep is eliminated [18].
2.3. Relationship between Melatonin, Body Temperature, and
the Sleep-Wake System. Melatonin levels vary concomitantly
with body temperature and sleep propensity across the 24-
hour day [21]. Speciﬁcally, under entrained conditions, the
late evening rise in circulating melatonin levels triggers a
thermoregulatory cascade, which, via an increase in the
blood ﬂow through distal skin regions and a subsequent
decrease in core body temperature (CBT), favors sleep
initiation (Figure 3)[ 21].
Core and distal body temperature levels show robust
circadian rhythms, which are controlled by the SCN through
projections to the dorsal subparaventricular zone (dSPZ)
and ultimately the medial preoptic region (Figure 2)[ 9].
Constant routine experiments have illustrated this circadian
variation for CBT, which reaches a peak in the late evening
(21:00–22:00) and a trough during the latter part of the
night (05:00–06:00) [24]. Distal skin temperature showed
an inverse time course, that is advanced by 25–100 minutes
with respect to the CBT curve [24]. Sleep is typically
initiated on the declining limb of the CBT curve [25],
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Figure 3: The relationship between melatonin secretion, body
temperature and sleepiness. The onset of melatonin secretion
during the early night causes an increase in heat loss at the
extremities (i.e., rising distal skin temperature, and distal-proximal
temperature gradient) and a drop in core body temperature,
followed by an increase in sleepiness. From [21].
and statistical regression analyses revealed that the distal-
proximal temperature gradient (a measure of heat loss at
the extremities) is the best predictor of a rapid SOL [26].
Exogenous melatonin administered during the day (when
endogenous levels are low) reduces CBT and increases
skin temperature, with concomitant increases in sleepiness
[27]. These results indicate that melatonin may achieve
its soporiﬁc eﬀects through a thermoregulatory pathway.
In addition to increasing sleepiness and sleep propensity,
exogenous melatonin can aﬀect sleep architecture [28–30],4 International Journal of Endocrinology
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Figure 4: The variation of gonadotropic and sex steroid hormones,
and the subsequent changes in daily body temperature across
the full menstrual cycle. During the pre-ovulatory FP, estrogen
levels are high. During the post-ovulatory LP, increasing levels
of circulating progesterone are observed, along with increased
daily body temperature. FSH, follicle stimulating hormone; LH,
luteinizing hormone; FP, follicular phase; LP, luteal phase. From
[22], as adapted from [23].
regardless of its eﬀect on body temperature [31, 32]. These
functional relationships and the localization of melatonin
receptors throughout the brain and periphery [33]s u g g e s t
that melatonin can aﬀect the sleep-wake and circadian
systems.
3.Normal MenstrualCycle
3.1. Hormonal Regulation of the Menstrual Cycle. The men-
strual cycle in healthy, ovulating females is regulated as well
asdeﬁnedbychangesinthegonadotropichormones,follicle-
stimulating hormone (FSH) and luteinizing hormone (LH),
and the sex steroid hormones, estrogen and progesterone
(Figure 4). At the start of the cycle, during the pre-ovulatory
follicularphase(FP),FSHstimulatesovarianfolliclestogrow
and develop at which point circulating estrogen levels begin
to rise and remain high throughout the FP. This culminates
inovulationatmid-cycle,whenLHlevelssurgeandstimulate
the release of an oocyte. The subsequent secretion of sex
hormones by the newly formed corpus luteum characterizes
this post-ovulatory LP, when progesterone is the dominant
hormone. If the egg is not fertilized, sex hormone levels drop
at the end of the LP and trigger the shedding of the uteral
lining (menstruation) [34].
3.2. Body Temperature Changes Associated with the Menstrual
Cycle. Hormone changes across the menstrual cycle result
in altered body temperature. Most notably, during the LP
compared to the FP, there is an increase of ∼0.3–0.4
◦C
in CBT levels (Figure 4)[ 35, 36] as well as a signiﬁcant
reduction in the amplitude of the circadian variation of CBT
[35–38], owing mainly to a blunted nocturnal decline of
CBT. Skin temperature and vascular blood ﬂow, which are
important thermoregulatory responses, are aﬀected by the
menstrual cycle. Increased threshold for sweating [39, 40]
and for vasodilation [39–41]a sw e l la sd e c r e a s e dt h e r m a l
conductance and skin blood ﬂow [42] is observed during the
LP compared to the FP.
This upward shift in the thermoregulatory set-point is
most likely due to progesterone, which possesses thermo-
genic properties [36, 43], and was shown to increase the
ﬁring rate of cold-sensitive (i.e., body warming) neurons in
the preoptic anterior hypothalamus (POAH) [44].
4.Sleep acrossthe MenstrualCyclein
Healthy Women
4.1. Standard Polysomnographic Sleep. A relatively limited
number of studies have addressed sleep-wake patterns across
the menstrual cycle in healthy women. These have indicated
that while sleep homeostasis [49, 51, 55] and quality [43,
49, 52] remain stable at diﬀerent menstrual phases, there
are observable changes in sleep architecture [49, 51–53]
(summarized in Table 1). Interestingly, women often report
subjective complaints of disturbed sleep during the late-LP
and premenstrual days, though polysomnography- (PSG-)
based estimates indicating disrupted sleep during this time
are less frequent [22]. Since most studies compared sleep at
only two menstrual phases (e.g., mid-FP versus mid- or late-
LP), inconsistencies still remain regarding the variation of
SWS [45, 47, 52, 53] and REM sleep [43, 47, 54, 55]a c r o s s
the menstrual cycle.
In the ﬁrst systematic study of sleep EEG across the
menstrual cycle in healthy women, nocturnal sleep was
recorded in the laboratory every other night throughout a
full cycle [49]. This study showed no menstrual cycle-related
change in SE (%), SOL (min), SWS (%) and wake after
sleep onset (WASO; min) [49]. Non-REM (NREM) sleep
and stage 2 sleep (%) signiﬁcantly increased in the LP, while
REM sleep (% of the NREM-REM sleep cycle) signiﬁcantly
decreased in the LP [49]. In a later study focusing on sleep-
disordered breathing and the menstrual cycle, Driver et al.
compared sleep at one visit during the FP and the LP [54].
They reported a signiﬁcant increase in stage 2 sleep (%)
during the LP, no change in SWS, and failed to replicate
the signiﬁcant decrease in REM sleep (%) generally reported
during this phase [54].
A variety of studies compared sleep at either two or three
phases of the menstrual cycle (mid-FP versus mid-LP [43,
53]; mid-FP versus late-LP [52, 55]; mid-FP versus mid-LP
versus menses [51]). Across three phases, REM sleep (min)
was signiﬁcantly reduced during the mid-LP compared to
the mid-FP, latency to stage 3 sleep was signiﬁcantly reducedInternational Journal of Endocrinology 5
Table 1: The variation of sleep across the menstrual cycle.
Authors
[Reference] Year Sample size Menstrual
phases studied
Signiﬁcant eﬀect of
menstrual phase
Signiﬁcant eﬀects
in PMDD (versus
NC)
Parry et al.
[45]
1989 n = 8 healthy
n = 8P M S
early-FP In healthy and PMS:
variation of stage 3
(min) and intermittent
awakening across cycle
↑ stage 2 (%)
across cycle late-FP
early-LP ↓ REM (min, %)
across cycle late-LP
Lee et al.
[46]
1990 n = 6 healthy FP none
↓ SWS (%) at both
phases
n = 7
symptomatic LP
↓ latency to stage 1
in LP
Ito et al.
[47]
1993 n = 7 healthy
menses
↓ SWS (min) during
early-LP and late-LP N/A late-FP
early-LP
late-LP
Ishizuka
et al. [48] 1994 n = 5 healthy 3 nights/week
across full cycle
↑ SFA during late-LP N/A
Driver et al.
[49] 1996 n = 9 healthy
menses ↑ NREM (%)
duringLP
N/A
early-FP
mid-FP
↑ stage 2 (%) duringLP
late-FP
ovulation ↓ REM
(%NREM-REM cycle
duration) during LP early-LP
mid-LP
↑ SFA during LP
late-LP
Chuong
et al. [50]
1997 n = 6 healthy
n = 3P M S
mid-FP
none none ovulation
mid-LP
Baker et al.
[51] 1999 n = 10 healthy
menses
mid-FP
mid-LP
↓ REM (%) during
mid-LP versus mid-FP
↓ latency to stage 3
during mid-LP versus
menses
N/A
Parry et al.
[52] 1999 n = 18 healthy
n = 23 PMDD
mid-FP
late-LP
In healthy andPMDD:
↑ ROL, ↓ stage 3 (min
and %), and ↓ REM
(min) during late-LP
In healthy: ↑ stage 1
(min, %) during
late-LP
none
Shibui et al.
[37]
2000 n = 8 healthy FP ↑ number of
SWS-containing naps
during LP
N/A
LP
Baker et al.
[43]
2001 n = 9 healthy mid-FP none N/A
mid-LP
Baker et al.
[53]
2002 n = 13 healthy mid-FP
↓ REM (%) during
mid-LP N/A
mid-LP
↑ SWS (%) during
mid-LP6 International Journal of Endocrinology
Table 1: Continued.
Authors
[Reference] Year Sample size Menstrual
phases studied
Signiﬁcant eﬀect of
menstrual phase
Signiﬁcant eﬀects
in PMDD (versus
NC)
Driver et al.
[54] 2005 n = 11 healthy FP
LP
↑ stage 2 (%) during LP N/A
Baker et al.
[55] 2007
n = 12 healthy
n = 9
PMS/PMDD
mid-FP
late-LP
In healthy and PMS:
↑ WASO (min),
↑microaraousals/hour,
and ↑ SFA during
late-LP
↑ ROL (min) at
both phases
Lamarche
et al. [56] 2007 n = 8 healthy
n = 10 PMS
FP
late-LP
In healthy and PMS:
↑ stage 2 (%),
↓ SWS (%), and ↓ REM
(%) during late-LP
none
PMS: premenstrual syndrome; PMDD: premenstrual dysphoric disorder; FP: follicular phase; LP: luteal phase; REM: rapid eye movement sleep; ROL: REM
onset latency; NREM: non-REM sleep; SWS: slow wave sleep; SFA: spindle frequency activity; WASO: wake after sleep onset.
during the mid-LP compared to menses, and there were no
signiﬁcant changes observed for stage 2 sleep (min) or SWS
[51]. Comparing the sleep of healthy women at the mid-
FP and mid-LP, one study found no signiﬁcant diﬀerences
between any sleep parameter (including SE, SOL, REM sleep
and SWS) [43], whereas another report detailed signiﬁcantly
decreased REM sleep (%) and signiﬁcantly increased SWS
(%) at the mid-LP compared to the mid-FP [53]. Focusing
on healthy women and women with premenstrual syndrome
(PMS) at the mid-FP and late-LP, Baker et al. reported that
healthy women had signiﬁcantly increased WASO (min) and
microarousals per hour during the late-LP compared to the
mid-FP, with no other signiﬁcant changes observed between
menstrual phases [55]. The results from eighteen healthy
controls studied by Parry et al. at the mid-FP and late-LP as
part of a larger study of sleep in PMDD found increases in
ROL (min) and stage 1 sleep (%), and decreased REM sleep
(min) and stage 3 (min and %) during the late-LP compared
to the mid-FP [52].
Two investigations studied PSG sleep across four phases
of the menstrual cycle [45, 47]. The ﬁrst, which included
eight healthy participants at the early-FP, the late-FP, the
early-LP and the late-LP, found signiﬁcant menstrual phase
variations for stage 3 sleep (min), with a trough at the late-
LP, and intermittent awakenings, with a peak at the late-LP
[45].Thesecond,whichincludedrecordingsofsevenhealthy
females at menses, the late-FP, the early-LP and the late-LP,
only found a signiﬁcant variation for SWS (min), which, like
the aforementioned study [45], was lowest during the LP
compared to the late-FP and menses [47].
Interested in studying the eﬀects of the menstrual cycle
on the circadian variation of sleep propensity, Shibui et al.
applied an ultra-rapid sleep-wake cycle procedure to eight
healthy females at the FP and LP [37]. Sleep propensity
(deﬁned in the study as the sum of the duration of stages
2, 3, 4 and REM sleep occurring at each 10-minute nap
trial) varied signiﬁcantly across the circadian day, but did
not diﬀer between menstrual phases. Their main ﬁnding was
that from 09:00 to 16:30, the number of naps containing
SWS was increased during the LP compared to the FP [37].
It should be noted, however, that their participants were
sleep-deprived for 24 hours preceding the start of the ultra-
rapid sleep-wake cycle, creating a situation that could have
increased the homeostatic pressure for SWS propensity, thus
potentially confounding these results.
4.2. Quantitative Sleep EEG. The eﬀects of menstrual phase
on quantitative sleep EEG have been investigated by a few
groups, yet results indicate a very consistent pattern of
ﬁndings, making the prominent increase in SFA during the
LP the most characteristic menstrual cycle associated sleep
change [48, 49, 55]( Table 1). The sleep of ﬁve healthy
young women was recorded by Ishizuka et al. at least three
nights per week across a complete menstrual cycle [48].
Deﬁningasleepspindleasactivitywithinthe11.11–16.13Hz
frequency range, the authors described a biphasic variation
in the frequency of spindles, with lowest values observed
during the FP (18 days before menstruation, near the mid-
FP) and highest values during the late-LP [48]. Similarly,
in the aforementioned study by Driver et al., which tracked
sleep changes throughout an entire menstrual cycle in nine
healthy women, SFA (here deﬁned as mean power density
within the 12.25–15.00Hz frequency range) was lowest
during the FP and reached peak values during the LP [49].
Maximum menstrual phase variation was observed within
the 14.25–15.00Hz band, and SWA (mean power density
within the 0.75–4.50Hz frequency range), a marker of sleep
homeostasis, was unchanged across the menstrual cycle [49].
Finally, in the recent study by Baker et al., healthy women
showed signiﬁcantly increased SFA (12–15Hz) during the
late-LP compared to the mid-FP, with the most prominent
peak again occurring in the 14.25–15.00Hz bin speciﬁcally
[55].
4.3. Summary and Future Steps. The most common sleep
ﬁndings across the menstrual cycle include decreases in REM
sleep, increases in stage 2 sleep and SFA, and no changes in
sleep propensity and quality (SOL and SE, resp.) during the
LP compared to the FP. Most studies agree with the absenceInternational Journal of Endocrinology 7
Table 2: The variation of hormonal rhythms across the menstrual cycle.
Authors
[Reference] Year Sample size Frequency of
sampling
Hormones
sampled
Menstrual
phases studied
Signiﬁcant eﬀect
of menstrual
phase
Signiﬁcant eﬀects
in PMDD (versus
NC)
Steiner et al. [57] 1984 n = 2 healthy 2x/hour for
24-hours
plasma cortisol FP none none
n = 2 PMS plasma PRL LP
Webley and
Leidenberger [58] 1986 n = 10
healthy
1x/4-hour for
24-hours
plasma
melatonin
FP ↑ melatonin
during LP N/A
LP
Brun et al. [59] 1987 n = 9 healthy 1x/night
urinary
immunoreactive
melatonin
across full cycle
↑ melatonin
during LP N/A
Brzezinski et al. [60] 1988 n = 14
healthy
1x/2-hour for
24-hours
Plasma
melatonin
plasma PRL
early-FP
none N/A ovulation
mid-LP
Berga and Yen [61] 1990 n = 10
healthy
1x/hour in
daytime
2x/hour in
nighttime
Plasma
melatonin
early-FP
none N/A late-FP
mid-LP
late-LP
Parry et al. [62] 1990 n = 8 healthy
n = 8P M S
2x/hour for
27-hours
plasma
melatonin
early-FP
none
↓ melatonin AUC
↓ melatonin
duration
melatonin
phase-advanced
late-FP
mid-LP
late-LP
Ito et al. [47] 1993 n = 4 healthy 1x/hour for
24-hours
plasma
melatonin
menses
none N/A late-FP
early-LP
late-LP
Parry et al. [63] 1994
n = 11
healthy
n = 21
PMDD
2x/hour for
27-hours
plasma cortisol mid-FP
late-LP
In healthy:
cortisol
phase-delayed in
late- LP
↑ PRL amplitude
at both phases
↑ PRL peak at
both phases
plasma PRL
plasma TSH
Cagnacci et al. [35] 1996 n = 7 healthy 4x/hour for
24-hours
plasma
melatonin
FP melatonin
phase-delay
during LP
N/A
LP
Parry et al. [64] 1996
n = 18
healthy
n = 23
PMDD
2x/hour for
27-hours
plasma TSH
plasma PRL
mid-FP
late-LP none
↑ PRL peak at
both phases TSH
phase-advanced
at both phases
Parry et al. [65] 1997
n = 11
healthy
n = 21
PMDD
2x/hour for
27-hours
plasma
melatonin
mid-FP
late-LP
In PMDD:
↓ AUC,
↓ amplitude,
↓duration,
delayed onset
during late-LP
↓ AUC at both
phases
↓ mean levels at
both phases
Bloch et al. [66] 1998
n = 10
healthy
n = 10 PMS
1x/day plasma cortisol
early-FP
none none
mid-FP
late-FP
ovulation
early-LP
mid-FP
late-FP8 International Journal of Endocrinology
Table 2: Continued.
Authors
[Reference] Year Sample size Frequency of
sampling
Hormones
sampled
Menstrual
phases studied
Signiﬁcant eﬀect
of menstrual
phase
Signiﬁcant eﬀects
in PMDD (versus
NC)
Wright and Badia
[67]
1999 n = 25
healthy
1x/hour for
24-hours
salivary
melatonin
FP none N/A
LP
Shibui et al. [37] 2000 n = 8 healthy 1x/hour for
24-hours
Plasma
melatonin
plasma cortisol
plasma TSH
FP
LP
↓ melatonin AUC
during LP
N/A
↓ cortisol
amplitude during
LP
↓ TSH amplitude
during LP
TSH phase-delay
during LP
Parry et al. [68] 2000
n = 15
healthy 2x/hour for
27-hours plasma cortisol mid-FP In healthy:
cortisol
phase-advanced
in LP
none
n = 15
PMDD late-LP
PMS: premenstrual syndrome; PMDD: premenstrual dysphoric disorder; FP: follicular phase; LP: luteal phase; PRL, prolactin; TSH: thyroid stimulating
hormone; AUC: area under the curve.
of changes in homeostatic sleep mechanisms (i.e., SWS and
SWA) at diﬀerent menstrual cycle phases, although some
inconsistencies remain (Table 1). Methodological diﬀerences
between the various studies might contribute to these
discrepancies. For example, menstrual phase delineation and
the number of sleep recordings across the cycle is often
diﬀerent between studies, and menstrual phase status is not
uniformly conﬁrmed with hormonal assays. Stabilization of
sleep-wake patterns before lab entry is not always done, even
though it is recommended to ensure a proper alignment of
sleep and circadian rhythms.
The changing sex hormone proﬁle across the men-
strual cycle may play a role in producing these LP-speciﬁc
sleep alterations. Speciﬁcally, progesterone, as well as its
neuroactive metabolites, can aﬀect sleep architecture, as
was illustrated by the ﬁndings that exogenous progesterone
[69] or megestrol acetate, a progesterone-receptor agonist
[70], reduced REM sleep in male participants. Likewise,
e x o g e n o u sp r o g e s t e r o n ei nr a t sr e d u c e dR E Ms l e e pw h i l e
lengthening ROL [71]. Furthermore, progesterone likely
aﬀects the sleep system through another indirect means,
namely by increasing body temperature during the LP. Sleep
architecture, like the timing of sleep propensity, is under a
circadian regulation, with highest REM sleep occurring at
times corresponding with the nadir of body temperature
[72]. The ﬁnding of reduced REM sleep during the LP,
when nocturnal body temperature is signiﬁcantly elevated
compared to the FP, is therefore interesting.
The LP-associated increase in SFA is most likely a result
of the neuroactive metabolites of progesterone acting as
agonistic modulators of central nervous system GABAA-
receptors in a benzodiazepine-like manner [49, 71]. Indeed,
progesterone administration enhanced spindle activity in
the rat [71] and in male participants (particularly those
who experienced an early allopregnanolone peak in response
to exogenous progesterone treatment) during the ﬁrst two
hours of sleep [69]. Like REM sleep, the temporal pattern
of SFA displays a robust circadian rhythm, with the peak
of low-frequency SFA (12.25–13.00Hz range) occurring
during periods of high endogenous melatonin concentra-
tion, whereas high-frequency SFA (14.25–15.50Hz range) is
minimal during these times and the greatest during periods
of low circulating melatonin [73].
The functional signiﬁcance of increased SFA during the
LP in women is still unknown. Since sleep spindles are
thought to have a sleep-protecting eﬀect via their blockage
of information processing to the cortex [74], increased
SFA may be the mechanism through which sleep quality is
maintainedatagoodleveldespitethechangingphysiological
and hormonal proﬁle associated with diﬀerent menstrual
cycle phases.
5. CircadianRhythms acrossthe Menstrual
Cycle in Healthy Women
It has been proposed that the menstrual cycle could
form a backdrop on which daily circadian rhythms are
expressed [22], and as such, circadian physiology can be
altered as a function of the changing hormone proﬁle
associated with diﬀerent menstrual phases (see Table 2 for
a summary). The most apparent of these alterations is CBT
(see above); yet other biological and hormonal rhythms,
including melatonin, cortisol, TSH, and PRL may also be
aﬀected. It was proposed that one implication of the altered
circadian rhythms observed during the menstrual cycle is
the production of a stable intrauterine environment [35].
Speciﬁcally, the authors point to the reduced eﬃcacy of
melatonin function during the LP, which results in a blunted
nocturnal decline of CBT and reduced circadian CBTInternational Journal of Endocrinology 9
amplitude, as a stabilizing factor which would encourage
proper implantation and development of a fertilized egg
[35]. However, these eﬀects may also contribute to the
increased incidence of subjective sleep complaints during the
LP.
5.1. Cortisol, TSH, and PRL across the Menstrual Cycle. A
small number of studies looked at rhythms of cortisol,
TSH, and PRL (Table 2). The circadian variation of cortisol
in healthy women was found to be phase-delayed by ∼1
hour [63], phase-advanced by ∼1h o u r[ 68] or decreased
in amplitude [37] during the LP compared to the FP.
PRL showed either a trend for increased amplitude during
the LP compared to the FP [64] or no change across
the menstrual cycle [60]. Sampling throughout an ultra-
rapid sleep-wake cycle, the TSH rhythm was found to be
decreased in amplitude and delayed by ∼80 minutes in
the LP compared to the FP [37]. Since limited number
and inconsistencies once again characterize these data, it is
important to replicate these studies using highly controlled
experimental conditions and adequate sample sizes.
5.2. Melatonin across the Menstrual Cycle. Melatonin is
known to play a role in reproductive physiology (see [75]f o r
a review). Studying menstrual-related changes in melatonin
secretion has been a topic of interest, though ﬁndings
remain equivocal (Table 2). An early study sampling plasma
melatonin every four hours during the FP and LP reported
a signiﬁcant increase in the total amount of secretion in
24 hours during the LP compared to the FP [58]. This
result was supported by the ﬁnding that nocturnal urinary
immunoreactive melatonin concentration (sampled nightly
over an entire menstrual cycle) was signiﬁcantly increased
during the LP compared to the FP [59]. However, in a well-
controlled study sampling every hour during the FP and LP
under constant conditions, the 24-hour area under the curve
(AUC) for plasma melatonin was signiﬁcantly decreased
duringtheLP,thoughothertimingmeasureswereunaﬀected
[37]. On the other hand, in an important study outlining
the role of melatonin on body temperature changes during
the LP, Cagnacci et al. found that while AUC was unchanged
between menstrual phases, there was a signiﬁcant delay of
∼110 minutes in the onset of nocturnal melatonin during
the LP [35]. Most other studies have found no change in
the patterns of melatonin secretion (including onset, oﬀset,
duration, midpoint, and AUC) across the menstrual cycle in
healthy women [47, 60–62, 65, 67]. Furthermore, strengths
of these studies were that they actually sampled melatonin
across the menstrual cycle (i.e., at four menstrual phase
[47, 61, 62, 65] as opposed to only two), or under constant
conditions [67].
5.3. The Interaction between Sex Hormones and Melatonin.
Evidence indicates that the pineal melatonin system and the
reproductive system interact, as was illustrated by a variation
in the number of cerebral and caudal arterial melatonin
binding sites in the rat throughout the estrous cycle [76]. An
interaction between the melatonin system and sex hormones
may have an inﬂuence on sleep and body temperature
rhythmsacross the menstrualcycle.Furthersupport forsuch
an interaction comes from the colocalization of melatonin
receptors with estrogen and progesterone receptors through-
out the brain and periphery. Speciﬁcally, considering areas
involved with the reproductive cycle, melatonin binding sites
were found at human [77]a n dr a t[ 78, 79] granulosa cells,
and melatonin was found in human ovarian follicular ﬂuid
[80].Furthermore,varioussourcesindicatethatreceptorsfor
melatonin,progesterone,andestrogencanallbefoundatthe
SCN [81, 82], POAH [82, 83], and pineal gland [84, 85].
Evidence of a functional interaction between melatonin
and sex hormones was presented by Cagnacci et al. in the
aforementioned study, who illustrated that women experi-
ence a progesterone-dependent resistance to the hypother-
mic eﬀects of melatonin during the LP [35]. While this
appears to support a functional antagonism between mela-
tonin and progesterone, there is also evidence for a positive
relationship between the two. Exogenous synthetic pro-
gestins (in the form of oral contraceptives) have a tendency
to increase melatonin secretion [58, 59, 67], and melatonin
treatment can enhance human chorionic gonadotropin-
stimulated progesterone production from human granu-
losa cells [86]. Conversely, estrogen appears to negatively
inﬂuence melatonin. For example, a low-estrogen envi-
ronment was associated with increased melatonin lev-
els in menopausal women, which was suppressed after
exogenous estrogen administration, and oopherectomy in
premenopausal women results in a signiﬁcant increase in
melatonin secretion [87]. Estrogen treatment also reduced
melatonin binding in the rat ovary [78]a n dr e d u c e d
melatonin synthesis in rat pinealocytes [88].
5.4. Summary and Future Steps. Most groups have found
no change in the circadian hormone proﬁles of melatonin,
cortisol, TSH, and PRL, though phase-delays were observed
for melatonin, cortisol, and TSH during the LP compared
to the FP (Table 2). Interestingly, when TSH and PRL were
found to change during the LP compared to the FP, the
directions of these changes (i.e., decreased TSH amplitude
and increased PRL amplitude) are the opposite of what
occurs after a partial nocturnal sleep deprivation [89],
thoughPSG-basedestimatesofsleepindicatetotalsleeptime
and SE are unchanged at diﬀerent menstrual phases (see
Table 1).
Most studies which sampled hormones at diﬀerent
menstrual phases did not do so under controlled conditions,
which are advised to limit the confounding eﬀects of envi-
ronmental factors (notably ambient light exposure, posture
changes, and the sleep-wake cycle), something which likely
contributes to these discrepancies [90]. Again, diﬀerences
in the methods of dividing the menstrual cycle as well
as sampling frequency (both across 24 hours and the
menstrual cycle) are likely to contribute to inconsistencies
in the literature. More studies need to be conducted before
deﬁnitive conclusions can be made regarding the circadian
variation of diﬀerent hormone secretions across the men-
strual cycle.10 International Journal of Endocrinology
6. Premenstrual Dysphoric Disorder
6.1. Deﬁnition and Symptoms of PMDD. PMDD is a mood
disorder aﬀecting 3%–8% of North American women [91].
As is implied by its name, the occurrence of PMDD is
deﬁned by its timing within the context of the menstrual
cycle. Symptoms typically begin during the late-LP and
remit after menses, with a complete absence of symptoms
during the FP. The DSM-IV lists a number of core symptoms
for PMDD, including depressed mood, anxiety/tension,
aﬀective lability, anger/irritability, and decreased interest,
each of which must reach suﬃcient severity to disrupt
social, academic, or professional functioning [92]. Among
thesemoodspeciﬁcsymptoms,sleepdisturbances(including
hypersomnia or insomnia, which is reported in as much
as 70% of PMDD women [92]) are often present during
the symptomatic LP. Since PMDD women may suﬀer from
altered hormone secretion and/or function (see below),
endocrinological factors and their inﬂuence on the sleep-
wake system are important to consider when discussing this
patient population.
6.2. Proposed Causes of PMDD. While the exact causes
of PMDD are still unknown, a variety of hypotheses
have been proposed which implicate endocrine or other
neurotransmitter systems. An altered sex hormone proﬁle
in PMDD has been reported, with lower progesterone
levels found in patients compared to controls [93, 94]
as well as decreased levels of the anxiolytic progesterone
metabolite allopregnanolone during the LP in patients [94,
95]. Progesterone produces its anxiolytic/hypnotic eﬀects via
allopregnanolone’s binding to GABAA-receptors [96, 97],
and some have found lower plasma GABA concentrations
[98]a n dad ec r e a s edG A B A A-receptor sensitivity [99] during
the LP in PMDD patients compared to controls. Results of
prior drug trials have found the most eﬀective treatment of
PMDD to date to be selective serotonin reuptake inhibitors
(SSRIs) and they have become the most common clinical
treatment for the disorder [100]. Experimental evidence
implicating the serotonergic system includes ﬁndings of
reduced plasma- [101] and whole-blood [102] serotonin
levels in patients compared to controls. This raises the
question of whether low serotonin levels could alter the
production of melatonin by the pineal gland, since serotonin
is a precursor for melatonin synthesis. Interestingly, PMDD
patients experience alterations in the timing and amount
of nocturnal melatonin secretion (see Section 8.2 below
[62, 65]), though it is unclear whether this is a cause or a
characteristic of the disorder.
7.Sleepacross the MenstrualCyclein
PMDD Women
7.1. Standard Polysomnographic Sleep and Qualitative Sleep
EEG. Although disrupted sleep is a characteristic symptom
of PMDD, results of sleep studies in these women have
been limited and inconsistent (Table 1). A preliminary study
comparing six healthy controls and three patients with PMS
(deﬁned as a set of emotional, physical, and behavioral
symptoms that occur with similar timing, but less severity,
as PMDD) failed to detect signiﬁcant diﬀerences in any
sleep parameter [50]. A larger study with 23 PMDD patients
and 18 controls also showed no intergroup diﬀerences,
though signiﬁcant menstrual phase eﬀects were noted. In
both groups, ROL (min) was increased, while REM sleep
(min) and stage 3 (min and %) were decreased in the LP
comparedtotheFP[52].Inacomparisonof“premenstrually
symptomatic” women (deﬁned with an increase of at least
30% in the Proﬁle of Mood States questionnaire during
the LP) with controls, women experiencing negative mood
symptoms during the LP showed decreased SWS (%) at both
menstrual phases as well as decreased latency to stage 1 sleep
and a trend for increased stage 2 sleep (%) in the LP [46].
Another study revealed that, compared to controls, PMS
patients had more stage 2 sleep (%) and less REM sleep (%),
and within these patients, stage 3 sleep (min; peaks near the
late-FP/early-LP) and intermittent awakenings (peaks near
the late-LP) varied signiﬁcantly across the menstrual cycle
[45]. More recently, a study including healthy women and
those with PMS found decreased SWS (%) and REM sleep
(%) as well as increased stage 2 (%) during the LP in both
groups [56].
To date, one study [55] investigated quantitative sleep
EEG in addition to standard PSG sleep in women with
PMS/PMDD. Results from this comparative study showed
thatwomenwithseverePMSandhealthycontrolsbothexpe-
rienced similar increases in WASO (min) and microarousals
per hour during the late-LP compared to the FP. Compared
to controls, PMS/PMDD women showed increased ROL
(min) in both menstrual phases. Similar to what has been
shown for healthy controls, PMS/PMDD women demon-
strated a menstrual variation for SFA (12–15Hz), with
marked increases during the late-LP. Interestingly, compared
to controls, these women showed a trend for increased EEG
activity in the 12-13Hz range [55].
7.2. Summary and Future Steps. Within-patients studies of
sleep across the menstrual cycle in PMS/PMDD patients
revealed reduced REM sleep during the LP compared to the
FP (Table 1). A signiﬁcant menstrual cycle variation of stage
3 sleep was observed, and two other studies found decreased
SWS or stage 3 sleep during the LP (Table 1).
PMS/PMDD women were found to have increased
WASO (min) and microarousals per hour during the LP
compared to the FP, indicating more disturbed sleep during
this symptomatic phase, but in that study, results were not
diﬀerent than healthy controls [55]. Similar to controls,
PMS/PMDD women experienced a signiﬁcant increase in
SFA during the LP compared to the FP, though, here, a trend
for increased activity in the 12-13Hz range was observed for
patients compared to controls (Table 1). Other comparisons
of PMS/PMDD women and healthy control women showed
patientstohaveincreasedstage2sleep,decreasedREMsleep,
or decreased SWS regardless of menstrual phase (Table 2). It
remains unclear what could be causing PMDD-speciﬁc sleep
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between sleep and parameters which are known to be altered
in the PMDD patients, like CBT, melatonin concentration,
and circadian phase.
IncreasedSFAduringtheLPinPMDDwomenmayserve
a sleep-protective role that is similar to what is proposed
for healthy women. The further increase in spindle activity
within the 12–13Hz range in PMS/PMDD, beyond what is
observed in controls, may illustrate a strengthening of this
eﬀect, which is especially relevant since PMDD patients are
most at risk for sleep disruptions during the LP. PMDD
women also experience altered REM sleep, which is a
hallmark of aﬀective disorder [103]. Interestingly, a sleep
restriction study in PMDD patients [52] (see Section 9.2)
demonstrated a signiﬁcant correlation between increasing
REM sleep and improved mood, which implies that the
reduced REM sleep sometimes observed in PMDD patients
may contribute to symptom development.
Important methodological issues should be addressed in
these studies as well, including (in addition to those men-
tioned previously) the high degree of patient heterogeneity
and diagnostic criteria used in these investigations. Only one
study [52] to date has addressed sleep in a singular group of
women whose diagnosis reached the DSM-IV standards to
be deﬁned as PMDD.
8. CircadianRhythms acrossthe Menstrual
Cycle in PMDD Women
8.1. Body Temperature across the Menstrual Cycle in PMDD
Women. Evidence suggests that PMDD patients can expe-
rience altered biological rhythms of body temperature
and hormone secretion that could contribute to symptom
development and/or exacerbation. An early study showed
that, compared to healthy controls, PMDD women had
signiﬁcantly elevated nocturnal CBT and a reduced CBT
amplitude during the LP [104]. Although a later study [105]
failed to replicate these results, the authors described a
decreased amplitude during the LP within PMDD patients,
as well as a trend for increased nocturnal CBT in PMDD
women compared to controls during the LP. Finally, a
nonsigniﬁcant trend for a phase-advanced temperature
minimum in PMDD patients compared to controls was
observed across the entire menstrual cycle [45]. Diﬀerences
in experimental techniques and data collection methods are
likely contributors to inconsistencies in the aforementioned
studies. For example, none of these controlled for the
confounding eﬀects of ambient light exposure, posture,
and sleep or by utilizing a constant routine protocol to
“unmask” the endogenous rhythm of CBT. Furthermore,
patient diagnostic criteria, sample size, and the frequency of
temperature recordings throughout the menstrual cycle all
varied between the studies. Future research should consider
these methodological issues.
8.2. Hormones across the Menstrual Cycle in PMDD Women.
A deﬁcient or altered circadian rhythm of melatonin
secretion (Table 2) was proposed as a mechanism causing
excessive daytime sleepiness and depressed mood in PMDD.
Some evidence supporting this notion, such as decreases in
amplitude, AUC, and mean levels, a phase-advance, and a
shorter duration of melatonin secretion in PMDD patients
compared to controls were reported [62, 65]. Additionally,
when comparing across the menstrual cycle within PMDD
patients, onset time was delayed, oﬀ-set time was advanced,
and duration of secretion was decreased in the LP compared
to the FP [65].
Reports of cortisol rhythms in PMDD are inconsistent
(Table 2). In one study, PMDD patients showed a tendency
for a phase-advance of the cortisol rhythm during the
LP compared to the FP [63], whereas in another, it was
delayed by ∼1 hour in the late-LP compared to the mid-
FP in healthy controls but unchanged in PMDD women
[68]. Three other studies failed to detect any signiﬁcant
diﬀerences between cortisol patterns in healthy controls and
PMS/PMDD patients [57, 66, 106].
Other hormonal rhythms, such as TSH and PRL, were
investigated in PMDD women, though the number of
studies is limited (Table 2). The peak time and acrophase of
TSH secretion was signiﬁcantly phase-advanced in patients
compared to controls, without any changes in concentration
[64]. Throughout the menstrual cycle, amplitude and peak
of PRL were higher in PMDD patients compared to controls
[63, 64], with a phase-advanced acrophase also detected in
these women [64]. In both of these studies, sleep patterns
and light-dark exposure were controlled for and stabilized.
Nevertheless, TSH and PRL proﬁles, both of which are
aﬀected by the sleep-wake cycle [14], were not obtained
under constant conditions (including sleep deprivation); so
masking eﬀects cannot be excluded.
8.3. Summary and Future Steps. The major ﬁndings regard-
ing altered hormone patterns in PMDD include decreased
melatonin secretion (AUC and amplitude) (Table 2), which
is reminiscent of ﬁndings in patients with major depressive
disorder (MDD) [107]. Lending further support to the idea
that PMDD women experience a phase-advance of circadian
rhythms similar to what is observed in MDD [108], these
women also experienced a tendency for phase-advanced
CBT rhythms as well as signiﬁcantly advanced melatonin
and TSH when compared with controls (Table 2). Since this
altered circadian physiology can contribute to an internal
desynchrony, resulting in poor sleep quality and mood
symptoms, more studies conducted under strict constant
routine conditions are necessary. A better understanding
of disturbed circadian rhythms in these women may lead
to improved chronotherapeutic techniques, which, while
similar to those already used in MDD and seasonal aﬀective
disorder [109], can be specialized to treat PMDD women.
9. Nonpharmaceutical PMDD Therapies
TargetingCircadianRhythms
Treatments of PMDD that target and correct circadian
rhythm abnormalities may be an eﬀective alternative to
drug-based therapies and may function via a realignment of
biological rhythms with the sleep-wake cycle.12 International Journal of Endocrinology
9.1. Light Therapy. Since PMDD patients seem to experience
a phase-advance of biological rhythms [45, 62, 64], it was
hypothesized that light therapy, particularly in the evening,
could have therapeutic eﬀects. Indeed, studies have found
that light therapy was eﬀective in signiﬁcantly reducing
depressivesymptomsinPMDDpatients[110–112].Whilean
initial study by Parry et al. [110] found that bright evening
light was more eﬀective than morning light, a follow-up
study by the same group [111] achieved similar beneﬁcial
eﬀects of symptom alleviation in PMDD patients using
bright white light in the morning, bright white light in
the evening, and dim red light in the evening (a putative
placebo). As the authors point out, a placebo eﬀect cannot
be excluded. A study by Lam et al. showed that compared to
baseline values, bright white light in the evening was more
eﬀective than dim red light in the evening in improving
symptoms [112]. This improvement may be achieved via
a resynchronization or phase-shift of biological rhythms,
since,comparedtoneutral-dimredlight,brighteveninglight
therapy was shown to delay the onset and oﬀset of melatonin
[65], increase the midpoint concentration of melatonin [65],
delay cortisol acrophase [63], and increase TSH nadir [63]i n
PMDD patients during the LP.
9.2. Sleep Deprivation. Total [113] and partial [114] sleep
deprivation (SD) was also shown to be eﬀective in reducing
depressive symptoms in PMDD patients, with as many as
80% of patients responding to this treatment [113]. In a
series of studies, Parry et al. described the physiological
eﬀects of selective SD in PMDD patients [64, 68, 105].
After early-SD (sleep times: 03:00–07:00) during the LP,
CBT [105], PRL [64], and TSH [64] acrophases were
phase-delayed, PRL amplitude was lowered [64], and TSH
amplitude was increased [64]. Late-SD (sleep times: 21:00–
01:00) increased CBT amplitude [105] and advanced the
acrophase of CBT [105], PRL [64], and cortisol [68], while
it delayed the TSH acrophase [64]. Additionally, late-SD also
resulted in a decreased PRL mesor [64] and increased TSH
mesor [64]. These changes, particularly the phase-delays
achieved in CBT and TSH, as well as amplitude changes
produced in CBT and PRL, indicate, that like light therapy,
SD might achieve its mood elevating eﬀects by targeting and
correcting abnormal circadian rhythms.
A study by Parry et al. demonstrated that, compared to
baseline late-LP, both early-SD and late-SD were eﬀective in
improving sleep quality in PMDD patients during a night
of recovery sleep in the LP. Reference [52] Total sleep time,
SE (%), SWS (min), and REM sleep (min and %) were
increased, whereas SOL (min), ROL (min), WASO, stage 1
sleep (min and %), and stage 2 sleep (%) were decreased.
The authors concluded that these therapeutic eﬀects were
accomplished, at least partially, via a correction of altered
circadianrhythmswhichaﬀectthesleep-wakecycle.Respon-
ders in this study showed improved mood scores during the
LP after early-SD, which were signiﬁcantly correlated with
changes in REM sleep and ROL, indicating REM parameters
to be important for the therapeutic eﬀects of SD. The
therapeutic eﬀects of SD, however, were only studied during
experimental nights and at a single recovery night [52];
therefore the duration of improvement in response to such
a treatment is unknown. These results are quite promising,
though, so more studies should be carried out along these
lines to determine the duration of such positive responses.
9.3. Summary and Future Steps. PMDD patients, like those
with MDD, have responded favorably to light therapy
during their symptomatic LP. Unlike MDD, however, in
which morning bright light had the greatest antidepressant
eﬀects [109], two studies demonstrated the most mood
improvement after evening bright light.
Studies have demonstrated that 50%–60% of MDD
patients respond to SD, with greater eﬀects on mood often
observed when SD is restricted to the latter portion of
the night [115]. PMDD patients responded with mood
improvements after both partial and total SD, and inter-
estingly these treatments often resulted in favorable shifts
of circadian physiology. Producing changes in the proper
direction to correct for altered rhythms in PMDD, early-
SD delayed rhythms of CBT and TSH, and decreased PRL
amplitude, while late-SD increased CBT amplitude, delayed
TSH and decreased PRL; however it also advanced rhythms
of CBT, PRL, and cortisol (not favorable). It should be
pointed out that the human circadian system, however, is
extremely sensitive to light [116, 117], and since ambient
light levels during waking episodes in these experiments
were kept at <100lux, the phase shifting eﬀects of light
exposure on these rhythms cannot be excluded. Based on
the single study discussed above [52], both early- and late-
SD produced improvements in objective sleep parameters
in PMDD patients, though future laboratory studies in
this direction should address how long these improvements
persist beyond a night of recovery sleep.
Preliminary results from our study investigating the
eﬀects of exogenous melatonin taken prior to nocturnal
sleep periods during the LP indicate that melatonin may
be beneﬁcial in alleviating sleep disruptions in PMDD
women [118]. It remains unclear whether melatonin exerts
these eﬀects on sleep via a chronobiotic/phase-shifting
mechanism, its sedative/soporiﬁc properties, a direct action
on hypothalamic sleep centers, or some other pathway.
10. Conclusions
Evidence from a variety of sources indicates that the
menstrual cycle interacts with circadian processes to alter the
expression of hormonal rhythms and sleep organization at
diﬀerent menstrual phases. This can lead to sleep alterations
during the LP in healthy women or more speciﬁc LP-
associated pathology like PMDD.
The most consistently observed menstrual cycle-related
changes in the sleep proﬁle of healthy women are a reduction
of REM sleep [49, 51–53, 56], with a maintenance of
homeostatic sleep mechanisms throughout the cycle [90],
and a robust variation of SFA across the menstrual cycle
[48,49,55],whichincreasesinassociationwithprogesterone
during the LP. Similarly, women with PMS/PMDD have alsoInternational Journal of Endocrinology 13
shown decreases in REM sleep [52, 56] and increases in SFA
[55] during the LP compared to the FP. Sleep complaints
during the LP are a symptom of PMDD. PSG-based studies
do not consistently demonstrate disrupted objective sleep in
PMDD (see Table 1), though some have shown increased
stage 2 sleep and decreases in SWS or REM sleep compared
to healthy women [45, 46].
The circadian variation of CBT is altered by the men-
s t r u a lc y c l ei nb o t hg r o u p so fw o m e n .M e a nl e v e l sa r e
increased (particularly during night time hours) [35, 36]
and the circadian amplitude is reduced [35–38] during LP.
Some studies have reported further nocturnal increases and
phase-advanced rhythms in PMS/PMDD patients compared
to healthy women [45, 104]. Generally, circadian hormone
rhythms are not signiﬁcantly altered across the menstrual
cycle (see Table 2), though variable results including both
increases [58, 59]a n dd e c r e a s e s[ 37] in melatonin as well as
changes in the timing of hormones [35] have been described.
DecreasednocturnalmelatoninsecretioninPMS/PMDDhas
also been observed [62, 65]. Finally, nonpharmacological
therapies for PMDD symptoms which target the sleep-wake
cycle and circadian rhythms, such as phototherapy [110–
112] and sleep deprivation [52, 65, 113, 114], are often
eﬀective in improving mood and sleep quality in these
patients.
Because of the persistent inconsistencies in the literature,
however, it is necessary to conduct more investigations of
circadian rhythm changes across the menstrual cycle. These
should make eﬀorts to assay sex hormone levels, utilize
constant conditions, control for light exposure, and record
sleep at numerous points throughout the menstrual and
circadian cycles. In light of the present discussion, it is
critical that researchers who are interested in including
femaleparticipantsinstudiesonsleepandcircadianrhythms
always make eﬀorts to control for and document menstrual
cycle phase. If the aim is to observe changes associated
with PMDD, participants should also be studied during the
symptomatic LP. When including healthy women in general
sleep/circadian experiments, it appears better to study them
during the mid-FP, in order to minimize interindividual
variability in physiological rhythms associated with the LP.
Investigations focusing on the interaction between circadian
physiology, sex hormones, and the sleep-wake cycle in
women across the lifespan will be important to understand
the role age-related neuroendocrine changes play in the
regulation of sleep and circadian rhythms.
Glossary of Abbreviations
PMDD: Premenstrual dysphoric disorder
TSH: Thyroid stimulating hormone
PRL: Prolactin
LP: Luteal phase
SWS: Slow wave sleep
SWA: Slow wave activity
SCN: Suprachiasmatic nucleus
SOL: Sleep onset latency
SE: Sleep eﬃciency
REM: Rapid eye movement
ROL: Rapid eye movement sleep onset latency
SFA: Spindle frequency activity
vSPZ: Ventral subparaventricular zone
DMH: Dorsomedial nucleus
TMN: Tuberomammillary nucleus
LC: Locus coeruleus
VLPO: Ventrolateral preoptic nucleus
CBT: Core body temperature
FSH: Follicle-stimulating hormone
LH: Luteinizing hormone
FP: Follicular phase
POAH: Preoptic anterior hypothalamus
PSG: Polysomnography
WASO: Wake after sleep onset
NREM: Non-REM
AUC: Area under the curve
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MDD: Major depressive disorder
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